Johnson & Johnson (JNJ) Cash and securities
- Total cash · latest quarter (USD): Value $20.76B; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-28..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-28..
Cash and securities
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $20.76B | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-28. $20.42B + $336.00M ≈ $20.76B |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 20.42B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 336.00M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Cash and current securities | 20.76B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-28 | $20.76B | (m) | $20.42B | $336.00M | (m) |
| 2026-03-29 | $22.05B | (m) | $21.69B | $363.00M | (m) |
| 2025-12-28 | $20.10B | (m) | $19.71B | $393.00M | (m) |
| 2025-09-28 | $18.56B | (m) | $18.23B | $331.00M | (m) |
| 2025-06-29 | $18.88B | (m) | $18.58B | $303.00M | (m) |
| 2025-03-30 | $38.78B | (m) | $38.47B | $307.00M | (m) |
| 2024-12-29 | $24.52B | (m) | $24.11B | $417.00M | (m) |
| 2024-09-29 | $20.30B | (m) | $19.98B | $317.00M | (m) |
| 2024-06-30 | $25.48B | (m) | $24.88B | $597.00M | (m) |
| 2024-03-31 | $26.22B | (m) | $25.47B | $745.00M | (m) |
| 2023-12-31 | $22.93B | (m) | $21.86B | $1.07B | (m) |
| 2023-10-01 | $23.51B | (m) | $19.73B | $3.78B | (m) |
| 2023-07-02 | $28.50B | (m) | $21.18B | $7.32B | (m) |
| 2023-04-02 | $24.61B | (m) | $19.17B | $5.44B | (m) |
| 2023-01-01 | $23.52B | (m) | $14.13B | $9.39B | (m) |
| 2022-10-02 | $34.08B | (m) | $11.36B | $22.72B | (m) |
| 2022-07-03 | $32.57B | (m) | $10.98B | $21.59B | (m) |
| 2022-04-03 | $30.39B | (m) | $10.46B | $19.93B | (m) |
| 2022-01-02 | $31.61B | (m) | $14.49B | $17.12B | (m) |
| 2021-10-03 | $31.00B | (m) | $17.60B | $13.40B | (m) |
| 2021-07-04 | $25.31B | (m) | $14.33B | $10.97B | (m) |
| 2021-04-04 | $24.62B | (m) | $12.67B | $11.95B | (m) |
| 2021-01-03 | $25.18B | (m) | $13.98B | $11.20B | (m) |
| 2020-09-27 | $30.78B | (m) | $18.96B | $11.82B | (m) |
| 2020-06-28 | $19.14B | (m) | $11.17B | $7.96B | (m) |
| 2020-03-29 | $18.02B | (m) | $15.53B | $2.49B | (m) |
| 2019-12-29 | $19.29B | (m) | $17.30B | $1.98B | (m) |
| 2019-09-29 | $17.95B | (m) | $16.25B | $1.70B | (m) |
| 2019-06-30 | $15.28B | (m) | $14.38B | $902.00M | (m) |
| 2019-03-31 | $15.34B | (m) | $14.73B | $602.00M | (m) |
| 2018-12-30 | $19.69B | (m) | $18.11B | $1.58B | (m) |
| 2018-09-30 | $19.36B | (m) | $16.06B | $3.31B | (m) |
| 2018-07-01 | $18.14B | (m) | $17.57B | $570.00M | (m) |
| 2018-04-01 | $15.20B | (m) | $14.64B | $565.00M | (m) |
| 2017-12-31 | $18.30B | (m) | $17.82B | $472.00M | (m) |
| 2017-10-01 | $16.23B | (m) | $15.72B | $510.00M | (m) |
| 2017-07-02 | $12.85B | (m) | $12.60B | $255.00M | (m) |
| 2017-04-02 | $39.34B | (m) | $20.91B | $18.43B | (m) |
| 2017-01-01 | $41.91B | (m) | $18.97B | $22.93B | (m) |
| 2016-10-02 | $40.43B | (m) | $18.20B | $22.23B | (m) |
| 2016-07-03 | $42.58B | (m) | $18.64B | $23.94B | (m) |
| 2016-04-03 | $39.85B | (m) | $13.86B | $25.99B | (m) |
| 2016-01-03 | $38.38B | (m) | $13.73B | $24.64B | (m) |
| 2015-09-27 | $37.31B | (m) | $13.64B | $23.67B | (m) |
| 2015-06-28 | $33.95B | (m) | $10.64B | $23.32B | (m) |
| 2015-03-29 | $31.32B | (m) | $11.99B | $19.33B | (m) |
| 2014-12-28 | $33.09B | (m) | $14.52B | $18.57B | (m) |
| 2014-09-28 | $33.01B | (m) | $13.82B | $19.19B | (m) |
| 2014-06-29 | $31.62B | (m) | $14.24B | $17.39B | (m) |
| 2014-03-30 | $29.39B | (m) | $19.72B | $9.67B | (m) |
| 2013-12-29 | $29.21B | (m) | $20.93B | $8.28B | (m) |
| 2013-09-29 | $25.23B | (m) | $17.20B | $8.02B | (m) |
| 2013-06-30 | $25.13B | (m) | $17.31B | $7.82B | (m) |
| 2013-03-31 | $21.67B | (m) | $14.86B | $6.81B | (m) |
| 2012-12-30 | $21.09B | (m) | $14.91B | $6.18B | (m) |
| 2012-09-30 | $19.77B | (m) | $15.49B | $4.29B | (m) |
| 2012-07-01 | $16.91B | (m) | $14.04B | $2.87B | (m) |
| 2012-04-01 | $33.85B | (m) | $30.27B | $3.58B | (m) |
| 2012-01-01 | $32.26B | (m) | $24.54B | $7.72B | (m) |
| 2011-10-02 | $30.93B | (m) | $15.62B | $15.31B | (m) |
| 2011-07-03 | $29.68B | (m) | $14.97B | $14.71B | (m) |
| 2011-04-03 | $26.87B | (m) | $22.36B | $4.51B | (m) |
| 2011-01-02 | $27.66B | (m) | $19.36B | $8.30B | (m) |
| 2010-10-03 | $22.13B | (m) | $14.34B | $7.79B | (m) |
| 2010-07-04 | $18.90B | (m) | $12.71B | $6.19B | (m) |
| 2010-04-04 | $18.01B | (m) | $13.74B | $4.27B | (m) |
| 2010-01-03 | $19.43B | (m) | $15.81B | $3.62B | (m) |
| 2009-09-27 | $14.34B | (m) | $11.86B | $2.48B | (m) |
| 2009-06-28 | $14.72B | (m) | $11.69B | $3.03B | (m) |
| 2009-03-29 | (m) | (m) | $12.59B | (m) | (m) |
| 2008-12-28 | $12.81B | (m) | $10.77B | $2.04B | (m) |
| 2008-09-28 | (m) | (m) | $14.02B | (m) | (m) |
| 2008-06-29 | (m) | (m) | $12.65B | (m) | (m) |
| 2007-12-30 | (m) | (m) | $7.77B | (m) | (m) |
| 2006-12-31 | (m) | (m) | $4.08B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |